IntrepiCyte

Company

IntrepiCyte is focused on licensing its unique, noninvasive, proprietary intranasal therapeutic cell delivery technology to target stem cells, immune cells, genetically engineered cells, and other therapeutic cells to damaged or diseased areas of the central nervous system in order to treat a variety of neurological, psychiatric, and behavioral disorders.

William H. Frey II, PhD, is the CEO of IntrepiCyte. Together with his collaborator, Lusine Danielyan, MD, they discovered and published the noninvasive intranasal method for bypassing the blood-brain barrier to deliver and target therapeutic cells to the brain and spinal cord. Although not associated with IntrepiCyte, Dr. Danielyan continues to make important contributions to the area of regenerative medicine. Earlier work by Dr. Frey led to his discovery in 1989 of the intranasal method of bypassing the blood-brain barrier to deliver and target therapeutic peptides (including intranasal insulin to treat Alzheimer’s and Parkinson’s) and other therapeutic molecules to the brain.